top of page

LEARN HOW WE APPROACH

REGENERATIVE CARDIAC MEDICINE OF TOMORROW

Innovative Approach

BREAKTHROUGH THERAPIES BY ACTIVATING REGENERATION & HEALING

RECARDIO (REgenerative CARDIOvascular Therapy) is a late clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe.

The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardia tissue after an injury.

DNA Strand Close-up

Science

TECHNOLOGY INNOVATION

Explore our cutting-edge technology initiatives aimed at revolutionizing cardiovascular care. From advanced diagnostics to digital health solutions, we are committed to leveraging technology for the betterment of patients worldwide.

Screenshot 2025-02-04 164807.png

Aiming to improve the body’s repair mechanisms by harnessing its own regenerative capacity, Recardio has now proceeded with the clinical evaluation of its lead candidate dutogliptin in cardiovascular indications to the global pivotal Phase 3 study. Other development programs are in earlier clinical and preclinical stage.

CLINICAL

CLINICAL STUDIES

Pipette and test plate

PARTNERING

WHY CHOOSE RECARDIO

RECARDIO’s therapeutic approach represents multiple product leads in the field of cardiology - more than the company can develop on its own.

​

To ensure optimal clinical development and success, RECARDIO is stepping up its collaboration activities and has already initiated joint development with interested pharmaceutical leaders in the field.

​

RECARDIO offers an exciting partnering and collaboration opportunity for experienced global investment groups and players in cardiac health.

bottom of page